San Diego—Oct. 27, 2022 – In a study published in the October 2022 issue of BRAIN, researchers from Rady Children's Institute for Genomic Medicine (RCIGM®) and the University of California San Diego School of Medicine describe their discovery of a new clinical syndrome, Neuro-Ocular DAGLA-related Syndrome (NODRS), in children with termination variants in the diacylglycerol lipase alpha (DAGLA) gene which encodes an enzyme in the brain that is involved in the signaling pathway of the endocannabinoid (eCB) system.
In the study, the authors assessed nine children from around the world who displayed unique neuro-ocular traits including developmental delays, difficulties with balance and walking, abnormal eye movements and head nodding. In each child, truncating variants in the last exon of DAGLA were found to be the cause of their unique pediatric syndrome. Because enzymatic activity was preserved, the observed mis-localization of the truncated protein may account for the observed phenotype.
"The phenotype and genotype are exceedingly well linked, which is unusual," said Jennifer Friedman, MD, the study's principal investigator, Clinical Professor of Neurosciences and Pediatrics at UC San Diego and Clinical Investigator at RCIGM. "The clustering of pathogenic DAGLA variants in these children may provide insight into the mechanism of disease."
DAGLA is a critical component of the eCB pathway, involved in a broad array of physiological functions. In the developing brain, the eCB signaling pathway has important influences on neural development, signaling, and brain repair. In the mature nervous system eCBs regulate short- and long-term suppression of neurotransmitter release. The ubiquitous nature of this pathway, and evolutionary conservation imply a central role in human health and disease. Despite this, no defined human disorders have previously been conclusively linked to mutations in the genes encoding components of this pathway until now.
"This is the first report linking an endocannabinoid system component, DAGLA, with a human genetic disorder, NODRS, and provides us with a better understanding of the role of endocannabinoids in health and disease," said Dr. Friedman. "Mutation in DAGLA was initially identified by researchers at The Scripps Research Translational Institute, whom we continue to collaborate with on this project through our Clinical and Translational Science Awards grant."
"This work is more than a description of a rare pediatric disease; it is the leading edge into better understanding how human health is impacted by cannabinoids; findings from this study may open the doorway to new, cannabis-derived medications for a broad range of disorders, since we know that cannabinoid receptors in the eCB system exist throughout a person's body, not just in the brain," said Matthew Bainbridge, PhD, Assistant Director of Translational Research at RCIGM and lead author. "This is an idea that we have not considered before because we did not know the gene involved and the exact role of these receptors. Knowing the gene means knowing the pathway and what types of therapeutics might be beneficial."
Dr. Bainbridge also believes that with a diagnosis, parents of a child living with NODRS now have the opportunity to come together as a community to share experiences, knowledge and hope with those who understand. Children presenting with these types of symptoms should be more easily diagnosed now that the gene for this super rare disease has been identified. "It's high time for a gene mutation linking the endocannabinoid system to human disease." Dr. Bainbridge concluded.
Co-authors include: Matthew N. Bainbridge, Aloran Mazumder, Daisuke Ogasawara, Rami Abou Jamra, Geneviève Bernard, Enrico Bertini, Lydie Burglen, Heidi Cope, Ali Crawford, Alexa Derksen, Leon Dure, Emily Gantz, Margarete Koch-Hogrebe, Anna C. E. Hurst, Sonal Mahida, Paige Marshall, Alessia Micalizzi, Antonio Novelli, Hongfan Peng, Rady Children's Institute for Genomic Medicine, Diana Rodriguez, Shira L. Robbins, S. Lane Rutledge, Roberta Scalise, Sophia Schließke, Vandana Shashi, Siddharth Srivastava, Isabella Thiffault, Sarah Topol, Undiagnosed Disease Network, Leila Qebibo, Dagmar Wieczorek, Benjamin Cravatt, Svasti Haricharan, Ali Torkamani and Jennifer Friedman
Funding for this research came, in part, from: Rady Children's Institute for Genomic Medicine; National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH); NIH Common Fund, Office of Strategic Coordination/Office of NIH Director; Canadian Institute of Health Research; Fonds de Recherche du Quebec – Santé; Compute Canada; Fondation du Grand défi Pierre Lavoie; Healthy Brains for Healthy Lives; National Center for Advancing Translational Sciences; Shaffer Family Foundation; Anne and Henry Zarrow Foundation; Children's Mercy Research Institute; and Genomic Answers for Kids program at Children's Mercy Kansas City.
About Rady Children's Institute for Genomic Medicine
We are transforming pediatric critical care by advancing disease-specific healthcare for infants and children with rare disease. Discoveries at the Institute are enabling rapid diagnosis and targeted treatment of critically ill newborns and pediatric patients at Rady Children's Hospital-San Diego and a growing network of more than 60 children's hospitals nationwide. The vision is to expand delivery of this life-changing technology to enable the practice of Rapid Precision Medicine™ at children's hospitals across the nation and the world. RCIGM is a non-profit, research institute embedded within Rady Children's Hospital and Health Center. Learn more at RadyGenomics.org
